COVID-19 Antibody Screening With SARS-CoV-2 Red Cell Kodecytes Using Routine Serologic Diagnostic Platforms

Simple item page
aut.relation.journalTransfusionen_NZ
aut.researcherPerry, Elizabeth
dc.contributor.authorNagappan, Ren_NZ
dc.contributor.authorFlegel, WAen_NZ
dc.contributor.authorSrivastava, Ken_NZ
dc.contributor.authorWilliams, ECen_NZ
dc.contributor.authorRyzhov, Ien_NZ
dc.contributor.authorTuzikov, Aen_NZ
dc.contributor.authorGalanina, Oen_NZ
dc.contributor.authorShilova, Nen_NZ
dc.contributor.authorSukhikh, Gen_NZ
dc.contributor.authorPerry, Hen_NZ
dc.contributor.authorBovin, NVen_NZ
dc.contributor.authorHenry, SMen_NZ
dc.date.accessioned2021-04-15T22:45:15Z
dc.date.available2021-04-15T22:45:15Z
dc.date.copyright2021en_NZ
dc.date.issued2021en_NZ
dc.description.abstractBACKGROUND: The COVID-19 pandemic is having a major global impact, and the resultant response in the development of new diagnostics is unprecedented. The detection of antibodies against SARS-CoV-2 has a role in managing the pandemic. We evaluated the feasibility of using SARS-CoV-2 peptide Kode Technology modified red cells (C19-kodecytes) to develop an assay compatible with existing routine serologic platforms. STUDY DESIGN AND METHODS: A panel of eight unique red cells modified using Kode Technology function-spacer-lipid constructs and bearing short SARS-CoV-2 peptides was developed (C19-kodecyte assay). Kodecytes were tested against undiluted expected antibody negative and positive plasma samples in manual tube and three column agglutination platforms. Parallel analysis with the same peptides in solid phase by enzyme immunoassays was performed. Evaluation samples included >120 expected negative blood donor samples and > 140 COVID-19 convalescent plasma samples, with independent serologic analysis from two centres. RESULTS: Specificity (reaction rate against expected negative samples) in three different column agglutionation (CAT) platforms against novel C19-kodecytes was >91%, which correlated with published literature. Sensitivity (reaction rate against expected positive convalescent, PCR confirmed samples) ranged from 82% to 97%, compared to 77% with the Abbott Architect SARS-CoV-2 IgG assay. Manual tube serology was less sensitive than CAT. Enzyme immuno assay results with some Kode Technology constructs also had high sensitivity. CONCLUSIONS: C19-kodecytes are viable for use as serologic reagent red cells for the detection of SARS-CoV-2 antibody with routine blood antibody screening equipment.en_NZ
dc.identifier.citationTransfusion. 2021; 61: 1171– 1180. https://doi.org/10.1111/trf.16327
dc.identifier.doi10.1111/trf.16327en_NZ
dc.identifier.issn1537-2995en_NZ
dc.identifier.urihttps://hdl.handle.net/10292/14122
dc.languageengen_NZ
dc.publisherWiley
dc.relation.urihttps://onlinelibrary.wiley.com/doi/10.1111/trf.16327
dc.rights© 2021 The Authors. Transfusion published by Wiley Periodicals LLC. on behalf of AABB. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
dc.rights.accessrightsOpenAccessen_NZ
dc.subjectInfectious disease testing; Intravenous immunoglobulin; Kodecyte
dc.titleCOVID-19 Antibody Screening With SARS-CoV-2 Red Cell Kodecytes Using Routine Serologic Diagnostic Platformsen_NZ
dc.typeJournal Article
pubs.elements-id398088
pubs.organisational-data/AUT
pubs.organisational-data/AUT/Faculty of Design & Creative Technologies
pubs.organisational-data/AUT/Faculty of Design & Creative Technologies/School of Engineering, Computer & Mathematical Sciences
pubs.organisational-data/AUT/Faculty of Design & Creative Technologies/School of Engineering, Computer & Mathematical Sciences/Centre for Kode Technology Innovation
pubs.organisational-data/AUT/Faculty of Health & Environmental Science
pubs.organisational-data/AUT/Faculty of Health & Environmental Science/School of Science
pubs.organisational-data/AUT/Faculty of Health & Environmental Science/School of Science/Biomedicine & Medical Diagnostics Department
pubs.organisational-data/AUT/PBRF
pubs.organisational-data/AUT/PBRF/PBRF Design and Creative Technologies
pubs.organisational-data/AUT/PBRF/PBRF Design and Creative Technologies/PBRF ECMS
pubs.organisational-data/AUT/PBRF/PBRF Health and Environmental Sciences
pubs.organisational-data/AUT/PBRF/PBRF Health and Environmental Sciences/HA Science 2018 PBRF
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Nagapan et al 2021.pdf
Size:
1.32 MB
Format:
Adobe Portable Document Format
Description:
Journal article
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
AUT Grant of Licence for Tuwhera Aug 2018.pdf
Size:
276.29 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
School of Science